Mr. Alejandro Antalich reports

BIOMIND LABS ANNOUNCES CAD $2.52 MILLION PRIVATE PLACEMENT FINANCING

Biomind Labs Inc. intends to complete a non-brokered private placement of up to 28 million units of the company at a price of nine cents per unit for gross proceeds of up to $2.52-million. Each unit will be composed of one common share in the capital of the company and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of 12 cents for a period of 24 months following the completion of the offering.

The offering is expected to close on or about Feb. 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance.

The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of Cboe Canada.

The net proceeds of the offering are expected to be used to advance Biomind's clinical development programs and regulatory preparations and for general working capital purposes.

About Biomind Labs Inc.

Biomind Labs is a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs and proprietary nanotechnology-based delivery systems for psychiatric and neurological conditions that affect the central nervous system. Leveraging translational neuroscience and formulation science, Biomind aims to optimize the pharmacological profile of key endogenous and naturally derived molecules to address unmet needs in the CNS therapeutics. The company is committed to rigorous clinical validation and patient-centric innovation.

We seek Safe Harbor.